[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599176":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":34,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Weizmann Institute of Science","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PERIBLOOD-MDS",null,"No intervention is given",[13],"Diagnostic Test: PERIBLOOD-MDS",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology",[9],[20],{"name":21,"affiliation":22,"role":23},"Liran Shlush","The Weizmann Institute of Science","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Clinical Trial Manage","CONTACT","+972522666230","gil.gonen-yaacovi@weizmann.ac.il",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Liran Shlush, Prof.","+972505109815","liran.shlush@weizmann.ac.il",[35,54],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of California San Diego","RECRUITING","San Diego","California","92093","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.16472,32.71571,{"lat":47,"lon":46},[50,52],{"name":51,"role":27,"phone":10,"phoneExt":10,"email":10},"Tan Tuyet",{"name":53,"role":23,"phone":10,"phoneExt":10,"email":10},"Rafael Bejar",{"facility":55,"status":37,"city":56,"state":57,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"University of Miami","Miami","Florida","33146",{"type":44,"coordinates":60},[61,62],-80.19366,25.77427,{"lat":62,"lon":61},[65,68],{"name":66,"role":27,"phone":67,"phoneExt":10,"email":10},"Helen Kattoura, Dr.","305-243-6438",{"name":69,"role":23,"phone":10,"phoneExt":10,"email":10},"Stephen Nimer",{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100599176","replacing-bone-marrow-diagnostics-with-peripheral-blood-analysis-in-cytopenia-patients-100599176",false,"NCT07081087","Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients","Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study","Inclusion Criteria:\n\n1. Patients aged 18 and up with suspected\u002Fconfirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia\n2. Platelets \\\u003C 150 × 10E9\u002FL or\n3. Absolute neutrophil count \\\u003C 1.8 × 10E9\u002FL or\n4. Hemoglobin (Hgb) \\\u003C 13 g\u002FdL (males) and \\\u003C 12 g\u002FdL (female) and\n5. For both sexes, no evidence of Iron, folinic acid, or B12 deficiency\n\nExclusion Criteria:\n\n1. Women who are pregnant\n2. Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS\u002FMM or any other gammopathy\n3. Lymphocytes \\> 5000\u002Ful\n4. Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.\n5. Patients who have undergone a bone marrow transplant.","ALL","18 Years",{"count":82,"type":83},1500,"ESTIMATED","OBSERVATIONAL","This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.",[87,88],"Cytopenia","MDS","2026-03-22",{"date":91,"type":92},"2026-03-25","ACTUAL",{"date":94,"type":92},"2025-06-01",{"date":96,"type":83},"2028-12",{"name":5,"class":6},2]